Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials
| Errataetall: |
CommentOn: Clin Microbiol Infect. 2023 Jan;29(1):13-21. - PMID 35863630 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 29(2023), 1 vom: 18. Jan., Seite 7-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gallagher, Jason C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Baricitinib |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 25.01.2023 published: Print-Electronic CommentOn: Clin Microbiol Infect. 2023 Jan;29(1):13-21. - PMID 35863630 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2022.10.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34772311X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34772311X | ||
| 003 | DE-627 | ||
| 005 | 20231226034518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2022.10.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM34772311X | ||
| 035 | |a (NLM)36257548 | ||
| 035 | |a (PII)S1198-743X(22)00530-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gallagher, Jason C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 25.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Clin Microbiol Infect. 2023 Jan;29(1):13-21. - PMID 35863630 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IL6 inhibitor | |
| 650 | 4 | |a Sarilumab | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Morgan, Rebecca L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 29(2023), 1 vom: 18. Jan., Seite 7-9 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:18 |g month:01 |g pages:7-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2022.10.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 18 |c 01 |h 7-9 | ||